FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

The ⁠Food and Drug ⁠Administration on Thursday proposed ​excluding the active ingredients in Novo Nordisk ‌and Eli Lilly's blockbuster obesity and diabetes medications from the ⁠list ⁠of drugs that outsourcing facilities can use for ​compounding in bulk.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.